Increasing Accuracy of Gross-to-Net Forecasts through High Quality Data, Use of Automation & Technology, Alongside Greater Partnerships with Internal & External Stakeholders, Creating Transparency & Precision in Calculating Accruals, Rebates and Ensuring Forecast Accuracy
Finance executives within pharmaceutical and biotechnology corporations face considerable challenges in the development of precise gross-to-net forecasts, requiring a delicate balance of data analysis and insights into the business model which ensure aspects such as rebates, accruals, and chargebacks are balanced and accounted for correctly. To produce an accurate forecast, executives must have deep knowledge of the product lifecycle, retail pipeline, and the many internal and external factors which ultimately impact net revenue, including legislative changes, private and public payer reimbursement, rebates and accruals. Enhancing the ability to accurately project net revenue, many pharmaceutical and biotechnology organizations look to embrace data science and technology into GTN forecasting, including tools which automate data collection and analysis, robotic accounting and even machine learning which will ultimately enable a more elastic approach.
The Q1 Pharmaceutical & Biotech Gross-to-Net Conference will provide finance and accounting executives with an in-depth learning opportunity focused on insightful and real-time case studies from organizations large and small, throughout the product lifecycle, where forecasting excellence has been achieved. Focusing on approaches to accuracy in data when working with varied stakeholders both internally and externally, including Pharmacy Benefit Managers, Wholesalers and both public and private payers, the meeting will ensure all perspectives are included in order to maximize the opportunity for practical improvement in forecasting. Analysis of tools integrated, processes taken to vet technology and drive return on investment will also allow participants an opportunity to view how like-minded organizations have embraced forward thinking technology to automate and streamline this highly technical and delicate function.
The Pharmaceutical and Biotech Gross-to-Net Conference has been approved for 7 CPE credits. Q1 Productions is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE Sponsors. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Suite 700, Nashville, TN 37219-2417. Website: www. nasba.org. Please note that in order to collect your CPE credits, you will be asked to sign in to each block of sessions to confirm your participation in that session. There are no pre-requisites for this course required.
Eric Jahnke | Sr. Marketing Manager | Q1 Productions
312.955.0424 | firstname.lastname@example.org